3 years ago

TauRx Pharmaceuticals Secures $119 Million to Accelerate Alzheimer's Treatment Development

  • TauRx Pharmaceuticals, a UK and Singapore-based company specializing in tau-based research for Alzheimer's disease, raised USD119M in funding

  • The company plans to use the funds to accelerate development plans for regulatory approval in China

  • This funding round follows a previous rights issue in 2021, raising USD64 million

  • TauRx plans to submit its HMTM drug for regulatory approval in the UK, US, and Canada in 2023, with other territories to follow.

      • ProblemHealthcare

      "Alzheimer's disease is a devastating neurodegenerative disease with no cure, leading to cognitive decline and memory loss, impacting millions of people worldwide."

      Solution

      "TauRx Pharmaceuticals is developing treatments and diagnostics for Alzheimer's and other neurodegenerative diseases by targeting tau protein aggregation, a key factor in disease progression."

      Covered on